Table 6.
Overall survival curve adjustment: HR and adjustment factor for patients with early metastatic melanoma (stage IIIB–IV M1a)
| Trial (drug, patient population) | HR for comparators | HR for GM-CSF | Adjustment factor |
|---|---|---|---|
| CA184-024 (dacarbazine, previously untreated) [8] | 0.32 | 0.20 | 0.64 |
| BRIM-3 (dacarbazine, previously untreated) [10] | 0.32 | 0.20 | 0.64 |
| BREAK-3 (dacarbazine, previously untreated) [9] | 0.29 | 0.20 | 0.70 |
| Daponte (dacarbazine, previously untreated) [25] | 0.39 | 0.20 | 0.52 |
| MDX010-20 (gp100, previously treated) [7] | 0.34 | 0.20 | 0.60 |
GM-CSF granulocyte-macrophage colony-stimulating factor, gp100 glycoprotein 100, HR hazard ratio